| TNFi (N = 71) | IL-6Ri (N = 79) | CTLA4-Ig (N = 58) | JAKi (N = 145) | p | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SE | Median | Mean | SE | Median | Mean | SE | Median | Mean | SE | Median | |||
Numerical variables | ||||||||||||||
 Age | 63.5 | 1.8 | 67 | 68.6 | 1.2 | 70 | 64.6 | 1.6 | 67.5 | 60.5 | 1.1 | 63 | < 0.01* | |
 Duration (months) | 163.3 | 13.3 | 155 | 169.8 | 14.0 | 136 | 182.9 | 16.8 | 143 | 164.3 | 9.6 | 123 | 0.76 | |
 CDAI | 27.4 | 1.5 | 26.2 | 28.9 | 1.6 | 26.2 | 26.7 | 1.4 | 24.8 | 26.2 | 1.0 | 25 | 0.5 | |
 HAQ-DI | 1.6 | 0.1 | 1.5 | 1.6 | 0.1 | 1.6 | 1.6 | 0.1 | 1.6 | 1.4 | 0.1 | 1.4 | 0.19 | |
 DAS28-CRP | 4.9 | 0.1 | 5.0 | 5.0 | 0.1 | 4.7 | 4.6 | 0.1 | 4.5 | 4.5 | 0.1 | 4.6 | 0.05 | |
 DAS28-ESR | 5.7 | 0.1 | 5.8 | 5.9 | 0.1 | 5.8 | 5.3 | 0.2 | 5.2 | 5.2 | 0.1 | 5.4 | < 0.01* | |
 GC dose (mg/day)a | 1.2 | 0.3 | 0 | 1.3 | 0.3 | 0 | 1.5 | 0.3 | 0 | 1.1 | 0.2 | 0 | 0.75 | |
 MTX dose (mg/week) | 5.5 | 0.7 | 6 | 4.9 | 0.6 | 0 | 6.0 | 0.9 | 5 | 7.1 | 0.5 | 8 | 0.04 | |
 Creatinine (mg/dL) | 0.9 | 0.1 | 0.68 | 0.9 | 0.1 | 0.76 | 0.7 | 0.0 | 0.64 | 0.7 | 0.0 | 0.65 | 0.03* | |
Categorical variables | N | % | N | % | N | % | N | % | p | |||||
 Gender | Male | 9 | 12.7 | 12 | 15.2 | 7 | 12.1 | 24 | 16.6 | 0.81 | ||||
Female | 62 | 87.3 | 67 | 84.8 | 51 | 87.9 | 121 | 83.4 | ||||||
 ACPA | Negative | 10 | 14.1 | 17 | 21.5 | 9 | 15.5 | 34 | 23.4 | 0.36 | ||||
Positive | 57 | 80.3 | 57 | 72.2 | 49 | 84.5 | 111 | 76.6 | ||||||
 Disease activity | LDA | 1 | 1.4 | 4 | 5.1 | 0 | 0.0 | 10 | 6.9 | 0.53 | ||||
MDA | 26 | 36.6 | 27 | 34.2 | 21 | 36.2 | 49 | 33.8 | ||||||
HDA | 44 | 62.0 | 48 | 60.8 | 37 | 63.8 | 85 | 58.6 | ||||||
 Use of MTX | 38 | 53.5 | 39 | 49.4 | 31 | 53.4 | 92 | 63.4 | 0.18 | |||||
 Use of GC | 19 | 26.8 | 16 | 20.3 | 19 | 32.8 | 29 | 20.0 | 0.20 | |||||
 Chronic lung disease | 25 | 35.2 | 32 | 40.5 | 20 | 34.5 | 41 | 28.3 | 0.31 | |||||
 Chronic heart disease | 2 | 2.8 | 12 | 15.2 | 2 | 3.4 | 2 | 0.7 | < 0.01 | |||||
 Osteoporosis with fracture | 3 | 4.2 | 3 | 1.3 | 3 | 5.2 | 1 | 0.7 | 0.98 | |||||
 Past use of b/tsDMARD | TL | 20 | 28.2 | 1 | 1.3 | 45 | 77.6 | 43 | 29.7 | N.A | ||||
TA | 14 | 19.7 | 53 | 67.1 | 0 | 0.0 | 22 | 15.2 | ||||||
TJ | 4 | 5.6 | 7 | 8.9 | 7 | 12.1 | 17 | 11.7 | ||||||
LA | 6 | 8.5 | 0 | 0.0 | 0 | 0.0 | 5 | 3.4 | ||||||
LJ | 2 | 2.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||||||
AJ | 0 | 0.0 | 1 | 1.3 | 0 | 0.0 | 0 | 0.0 | ||||||
TLA | 20 | 28.2 | 0 | 0.0 | 0 | 0.0 | 24 | 16.6 | ||||||
TAJ | 0 | 0.0 | 12 | 15.2 | 0 | 0.0 | 4 | 2.8 | ||||||
TLJ | 1 | 1.4 | 2 | 2.5 | 6 | 10.3 | 11 | 7.6 | ||||||
TLAJ | 4 | 5.6 | 3 | 3.8 | 0 | 0.0 | 19 | 13.1 | ||||||
 vD2T RA | 25 | 35.2 | 17 | 21.5 | 6 | 10.3 | 58 | 40.0 | < 0.01* |